Prospective Pilot Study Of The Effect Of Rifaximin On B-cell Dysregulation In Cirrhosis Due To Chronic Hepatitis C Infection
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Rifaximin (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics
- 26 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.
- 26 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Aug 2018.
- 26 Jan 2018 Status changed from recruiting to active, no longer recruiting.